BRPI0716171A2 - composto, composiÇço farmacÊutica e uso de um composto. - Google Patents

composto, composiÇço farmacÊutica e uso de um composto.

Info

Publication number: BRPI0716171A2
Authority: BR; Brazil
Prior art keywords: compound; pharmaceutical composition; pharmaceutical; composition
Prior art date: 2006-09-07

Application number

BRPI0716171-9A2A

Other languages

English (en)

Inventor

Martin Bolli

Claus Mueller

Boris Mathys

David Lehmann Voss

Oliver Nayler

Joerg Velker

Beat Steiner

Original Assignee

Actelion Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-07

Filing date

2007-09-06

Publication date

2013-09-17

2007-09-06 Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd

2013-09-17 Publication of BRPI0716171A2 publication Critical patent/BRPI0716171A2/pt

2017-12-26 Publication of BRPI0716171A8 publication Critical patent/BRPI0716171A8/pt

2021-05-11 Publication of BRPI0716171B1 publication Critical patent/BRPI0716171B1/pt

2021-05-25 Publication of BRPI0716171B8 publication Critical patent/BRPI0716171B8/pt

Links

150000001875 compounds Chemical class 0.000 title 2
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Otolaryngology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

BRPI0716171A 2006-09-07 2007-09-06 composto, composição farmacêutica e uso de um composto BRPI0716171B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IBPCT/IB06/053147		2006-09-07
IB2006053147		2006-09-07
PCT/IB2007/053594 WO2008029371A1 (en)	2006-09-07	2007-09-06	Pyridin-4-yl derivatives as immunomodulating agents

Publications (4)

Publication Number	Publication Date
BRPI0716171A2 true BRPI0716171A2 (pt)	2013-09-17
BRPI0716171A8 BRPI0716171A8 (pt)	2017-12-26
BRPI0716171B1 BRPI0716171B1 (pt)	2021-05-11
BRPI0716171B8 BRPI0716171B8 (pt)	2021-05-25

Family

ID=38983600

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0716171A BRPI0716171B8 (pt)	2006-09-07	2007-09-06	composto, composição farmacêutica e uso de um composto

Country Status (26)

Country	Link
US (1)	US8580824B2 (pt)
EP (1)	EP2069336B1 (pt)
JP (1)	JP5253401B2 (pt)
KR (1)	KR101470659B1 (pt)
CN (1)	CN101511827B (pt)
AR (1)	AR062683A1 (pt)
AU (1)	AU2007292993B2 (pt)
BR (1)	BRPI0716171B8 (pt)
CA (1)	CA2661105C (pt)
CL (1)	CL2007002593A1 (pt)
CY (1)	CY1113727T1 (pt)
DK (1)	DK2069336T3 (pt)
ES (1)	ES2400533T3 (pt)
HR (1)	HRP20130181T1 (pt)
IL (1)	IL197393A (pt)
MA (1)	MA30718B1 (pt)
MX (1)	MX2009002233A (pt)
MY (1)	MY149853A (pt)
NO (1)	NO342156B1 (pt)
NZ (1)	NZ576060A (pt)
PL (1)	PL2069336T3 (pt)
PT (1)	PT2069336E (pt)
RU (1)	RU2447071C2 (pt)
SI (1)	SI2069336T1 (pt)
TW (1)	TWI392671B (pt)
WO (1)	WO2008029371A1 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2069335T3 (pl) *	2006-09-08	2013-05-31	Actelion Pharmaceuticals Ltd	Pochodne pirydyn-3-ylu jako środki immunomodulujące
ES2393412T3 (es) *	2006-09-21	2012-12-21	Actelion Pharmaceuticals Ltd.	Derivados de fenilo y su uso como inmunomoduladores
EP2109364A4 (en)	2006-12-15	2010-04-14	Abbott Lab	NOVEL OXADIAZONE COMPOUNDS
JO2701B1 (en)	2006-12-21	2013-03-03	جلاكسو جروب ليميتد	Vehicles
BRPI0808789A2 (pt) *	2007-03-16	2014-08-12	Actelion Pharmaceuticals Ltd	Compostos e composição farmacêutica de derivados aminopiridina e uso destes
PT2195311E (pt) *	2007-08-17	2011-05-25	Actelion Pharmaceuticals Ltd	Derivados de piridina como moduladores do receptor s1p1/edg1
KR20100092473A (ko) *	2007-11-01	2010-08-20	액테리온 파마슈티칼 리미티드	신규한 피리미딘 유도체
EP2262799B1 (en) *	2008-03-06	2012-07-04	Actelion Pharmaceuticals Ltd.	Pyridine compounds
WO2009109907A1 (en) *	2008-03-06	2009-09-11	Actelion Pharmaceuticals Ltd	Novel pyrimidine-pyridine derivatives
CA2715317A1 (en) *	2008-03-07	2009-09-11	Actelion Pharmaceuticals Ltd	Novel aminomethyl benzene derivatives
WO2009109872A1 (en) *	2008-03-07	2009-09-11	Actelion Pharmaceuticals Ltd	Pyridin-2-yl derivatives as immunomodulating agents
PL2278960T5 (pl)	2008-03-17	2020-06-29	Actelion Pharmaceuticals Ltd.	Schemat dawkowania dla selektywnego agonisty receptora sip1
TWI490214B (zh) *	2008-05-30	2015-07-01	艾德克上野股份有限公司	苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
US8580841B2 (en)	2008-07-23	2013-11-12	Arena Pharmaceuticals, Inc.	Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
HRP20160890T1 (hr)	2008-08-27	2016-09-23	Arena Pharmaceuticals, Inc.	Derivati supstituirane tricikličke kiseline kao agonisti s1p1-receptora korisni u liječenju autoimunih i upalnih poremećaja
JP2012515787A (ja)	2009-01-23	2012-07-12	ブリストル−マイヤーズスクイブカンパニー	自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
WO2010085582A1 (en)	2009-01-23	2010-07-29	Bristol-Myers Squibb Company	Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
ES2405054T3 (es)	2009-01-23	2013-05-30	Bristol-Myers Squibb Company	Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
ES2517265T3 (es) *	2009-03-03	2014-11-03	Merck Serono S.A.	Derivados de oxadiazol piridina
US20120035372A1 (en) *	2009-04-17	2012-02-09	Ishihara Sangyo Kaisha, Ltd.	method for producing 2-halogeno-6-substituted-4-trifluoromethylpyridine
DE102009002514A1 (de) *	2009-04-21	2010-10-28	Evonik Degussa Gmbh	Verfahren zur Herstellung von substituierten 1,4-Chinonmethiden
CA2767585C (en) *	2009-07-16	2017-09-26	Actelion Pharmaceuticals Ltd	Pyridin-4-yl derivatives
US8399451B2 (en)	2009-08-07	2013-03-19	Bristol-Myers Squibb Company	Heterocyclic compounds
JP5856980B2 (ja)	2010-01-27	2016-02-10	アリーナファーマシューティカルズ，インコーポレイテッド	（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
CN105503882B (zh)	2010-03-03	2019-07-05	艾尼纳制药公司	制备s1p1受体调节剂及其晶体形式的方法
ES2548683T3 (es)	2010-04-23	2015-10-20	Bristol-Myers Squibb Company	Amidas del ácido 4-(5-isoxazolil o 5-pirrazolil-1,2,4-oxadiazol-3-il)-mandélico como agonistas de receptor de esfingosina-1-fosfato 1
US8822510B2 (en)	2010-07-20	2014-09-02	Bristol-Myers Squibb Company	Substituted 3-phenyl-1,2,4-Oxadiazole compounds
EP2619190B1 (en)	2010-09-24	2015-08-12	Bristol-Myers Squibb Company	Substituted oxadiazole compounds and their use as s1p1 agonists
MA34910B1 (fr) *	2011-01-19	2014-02-01	Actelion Pharmaceuticals Ltd	Dérivés de 2-methoxy-pyridin-4-yl
SMT202000298T1 (it)	2012-08-17	2020-07-08	Actelion Pharmaceuticals Ltd	Processo per la produzione di (2z,5z)-5-(3-cloro-4((r)-2,3-diidrossipropossi) benziliden)-2-(propilimmino)-3-(o-tolil)tiazolidin-4-one e intermedio usato in detto processo
NZ713080A (en) *	2013-03-15	2020-06-26	Idorsia Pharmaceuticals Ltd	Pyridin-4-yl derivatives
PL3242666T3 (pl)	2015-01-06	2025-02-17	Arena Pharmaceuticals, Inc.	Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
PH12017502097B1 (en)	2015-05-20	2023-05-05	Idorsia Pharmaceuticals Ltd	Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
US10111841B2 (en)	2015-06-19	2018-10-30	University Of South Florida	Stabilization of alcohol intoxication-induced cardiovascular instability
BR112017027656B1 (pt)	2015-06-22	2023-12-05	Arena Pharmaceuticals, Inc.	Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
WO2017004609A1 (en) *	2015-07-02	2017-01-05	Exelixis, Inc.	Thiadiazole modulators of s1p and methods of making and using
WO2017004610A1 (en) *	2015-07-02	2017-01-05	Exelixis, Inc.	Tercyclic s1p3-sparing, s1p1 receptor agonists
WO2017004608A1 (en) *	2015-07-02	2017-01-05	Exelixis, Inc.	Oxadiazole modulators of s1p methods of making and using
MX2019009841A (es)	2017-02-16	2020-01-30	Arena Pharm Inc	Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
MX2019009843A (es)	2017-02-16	2020-01-30	Arena Pharm Inc	Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales.
CN107311994A (zh) *	2017-08-14	2017-11-03	淄博职业学院	一种s1p‑1受体激动剂药物分子的新型合成方法
PE20201170A1 (es)	2017-11-01	2020-10-28	Bristol Myers Squibb Co	Compuestos biciclicos en puente como moduladores del receptor farnesoide x
CN109956912B (zh) *	2017-12-26	2021-10-22	中国医学科学院药物研究所	含二苯基噁二唑的羧酸类化合物、其制备方法及医药用途
CA3102136A1 (en)	2018-06-06	2019-12-12	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the s1p1 receptor
CN112955431A (zh)	2018-09-06	2021-06-11	艾尼纳制药公司	可用于治疗自身免疫性病症和炎性病症的化合物

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3647809A (en) *	1968-04-26	1972-03-07	Chinoin Gyogyszer Es Vegyeszet	Certain pyridyl-1 2 4-oxadiazole derivatives
AU7686891A (en)	1990-04-05	1991-10-30	American National Red Cross, The	A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
AU653957B2 (en)	1990-09-20	1994-10-20	Merrell Dow Pharmaceuticals Inc.	1-aryl-3-pyridinyl-2-propene-1-ones
DE4429465A1 (de) *	1994-08-19	1996-02-22	Bayer Ag	Verfahren zur Herstellung von 2-Halogenpyridinaldehyden und neue 2-Halogenpyridinaldehyde
US6423508B1 (en)	1998-03-09	2002-07-23	Smithkline Beecham Corporation	Polynucleotide sequences of human EDG-1c
DE19904389A1 (de)	1999-02-04	2000-08-10	Bayer Ag	Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe
KR100875222B1 (ko)	1999-08-19	2008-12-19	아스트라제네카 아베	헤테로폴리사이클릭 화합물 및 간접 글루타메이트 수용체길항제로서의 그들의 용도
MXPA03007513A (es)	2001-02-21	2004-07-30	Nps Pharma Inc	Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
JP4430941B2 (ja)	2002-01-18	2010-03-10	メルクエンドカムパニーインコーポレーテッド	Ｅｄｇ受容体作動薬
ATE448193T1 (de)	2002-01-18	2009-11-15	Merck & Co Inc	ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
US20040058894A1 (en) *	2002-01-18	2004-03-25	Doherty George A.	Selective S1P1/Edg1 receptor agonists
JP2005533058A (ja)	2002-06-17	2005-11-04	メルク　エンド　カムパニー　インコーポレーテッド	Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
DE10237883A1 (de) *	2002-08-19	2004-03-04	Merckle Gmbh Chem.-Pharm. Fabrik	Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie
WO2004035538A1 (en)	2002-10-15	2004-04-29	Merck & Co., Inc.	Process for making azetidine-3-carboxylic acid
US20050004186A1 (en)	2002-12-20	2005-01-06	Pfizer Inc	MEK inhibiting compounds
AU2004240586A1 (en)	2003-05-15	2004-12-02	Merck & Co., Inc.	3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists
WO2005014525A2 (en)	2003-08-12	2005-02-17	Mitsubishi Pharma Corporation	Bi-aryl compound having immunosuppressive activity
RU2390519C2 (ru) *	2003-08-29	2010-05-27	Оно Фармасьютикал Ко., Лтд.	Соединение, способное к связыванию с рецептором s1p, и его фармацевтическое применение
US20070043014A1 (en) *	2003-10-01	2007-02-22	Merck & Co., Inc.	3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
EP1697333A4 (en) *	2003-12-17	2009-07-08	Merck & Co Inc	(3,4-DISUBSTITUTED) PROPANE ACID BOXYLATES AS AGONISTS OF THE S1P (EDG) RECEPTOR
EP1758579A1 (en)	2004-05-29	2007-03-07	7TM Pharma A/S	Crth2 receptor ligands for medicinal uses
WO2006010379A1 (en) *	2004-07-29	2006-02-02	Actelion Pharmaceuticals Ltd.	Novel thiophene derivatives as immunosuppressive agents
CA2583681A1 (en)	2004-10-22	2006-05-04	Merck & Co., Inc.	2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
BRPI0519012A2 (pt) *	2004-12-13	2008-12-23	Ono Pharmaceutical Co	derivado do Ácido aminocarboxÍlico e seu uso medicinal
KR20080002850A (ko) *	2005-03-23	2008-01-04	액테리온 파마슈티칼 리미티드	신규한 티오펜 유도체
US7605269B2 (en)	2005-03-23	2009-10-20	Actelion Pharmaceuticals Ltd.	Thiophene derivatives as Sphingosine-1-phosphate-1 receptor agonists
CA2602474C (en) *	2005-03-23	2014-06-10	Actelion Pharmaceuticals Ltd	Hydrogenated benzo (c) thiophene derivatives as immunomodulators
JP2008534689A (ja) *	2005-04-05	2008-08-28	ファーマコペイア，インコーポレイテッド	免疫抑制のためのプリン及びイミダゾピリジン誘導体
WO2006115188A1 (ja)	2005-04-22	2006-11-02	Daiichi Sankyo Company, Limited	ヘテロ環化合物
US8017631B2 (en)	2005-04-26	2011-09-13	Neurosearch A/S	Oxadiazole derivatives and their medical use
WO2006131336A1 (en)	2005-06-08	2006-12-14	Novartis Ag	POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
WO2006135694A2 (en) *	2005-06-10	2006-12-21	Acadia Pharmaceuticals Inc.	Uii-modulating compounds and their use
US7951794B2 (en) *	2005-06-24	2011-05-31	Actelion Pharmaceuticals Ltd.	Thiophene derivatives
CN101203220A (zh)	2005-06-28	2008-06-18	阿斯利康(瑞典)有限公司	新用途
AR057894A1 (es) *	2005-11-23	2007-12-26	Actelion Pharmaceuticals Ltd	Derivados de tiofeno
TWI404706B (zh) *	2006-01-11	2013-08-11	Actelion Pharmaceuticals Ltd	新穎噻吩衍生物
AU2007209051A1 (en) *	2006-01-24	2007-08-02	Actelion Pharmaceuticals Ltd	Novel pyridine derivatives
GB0601744D0 (en)	2006-01-27	2006-03-08	Novartis Ag	Organic compounds
KR20080096780A (ko)	2006-02-21	2008-11-03	유니버시티 오브 버지니아 페이턴트 파운데이션	Ｓ１ｐ 수용체 효능제로서의 페닐-시클로알킬 및 페닐-헤테로시클릭 유도체
EP2258700A1 (en) *	2006-05-09	2010-12-08	Pfizer Products Inc.	Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
AR061841A1 (es) *	2006-09-07	2008-09-24	Actelion Pharmaceuticals Ltd	Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores.
PL2069335T3 (pl)	2006-09-08	2013-05-31	Actelion Pharmaceuticals Ltd	Pochodne pirydyn-3-ylu jako środki immunomodulujące
ES2393412T3 (es) *	2006-09-21	2012-12-21	Actelion Pharmaceuticals Ltd.	Derivados de fenilo y su uso como inmunomoduladores
CN101522646A (zh)	2006-09-29	2009-09-02	诺瓦提斯公司	具有抗炎和免疫抑制特性的二唑衍生物
JP2008120794A (ja)	2006-10-16	2008-05-29	Daiichi Sankyo Co Ltd	ヘテロ環化合物を含有する医薬組成物
US20080138955A1 (en) *	2006-12-12	2008-06-12	Zhiyuan Ye	Formation of epitaxial layer containing silicon
EP2109364A4 (en)	2006-12-15	2010-04-14	Abbott Lab	NOVEL OXADIAZONE COMPOUNDS
WO2008091967A1 (en)	2007-01-26	2008-07-31	Smithkline Beecham Corporation	Chemical compounds
BRPI0808789A2 (pt) *	2007-03-16	2014-08-12	Actelion Pharmaceuticals Ltd	Compostos e composição farmacêutica de derivados aminopiridina e uso destes
PT2195311E (pt) *	2007-08-17	2011-05-25	Actelion Pharmaceuticals Ltd	Derivados de piridina como moduladores do receptor s1p1/edg1
KR20100092473A (ko) *	2007-11-01	2010-08-20	액테리온 파마슈티칼 리미티드	신규한 피리미딘 유도체
MX2010005889A (es) *	2007-12-10	2010-06-22	Actelion Pharmaceuticals Ltd	Derivados de tiofeno como agonistas de s1p1/edg1.
EP2262799B1 (en) *	2008-03-06	2012-07-04	Actelion Pharmaceuticals Ltd.	Pyridine compounds
WO2009109907A1 (en) *	2008-03-06	2009-09-11	Actelion Pharmaceuticals Ltd	Novel pyrimidine-pyridine derivatives
CA2715317A1 (en) *	2008-03-07	2009-09-11	Actelion Pharmaceuticals Ltd	Novel aminomethyl benzene derivatives
WO2009109872A1 (en) *	2008-03-07	2009-09-11	Actelion Pharmaceuticals Ltd	Pyridin-2-yl derivatives as immunomodulating agents
EP3782991A1 (en)	2008-05-14	2021-02-24	The Scripps Research Institute	Novel modulators of sphingosine phosphate receptors
CA2767585C (en)	2009-07-16	2017-09-26	Actelion Pharmaceuticals Ltd	Pyridin-4-yl derivatives

2007
- 2007-09-06 PT PT78262870T patent/PT2069336E/pt unknown
- 2007-09-06 NZ NZ576060A patent/NZ576060A/en not_active IP Right Cessation
- 2007-09-06 AU AU2007292993A patent/AU2007292993B2/en not_active Ceased
- 2007-09-06 US US12/310,801 patent/US8580824B2/en active Active
- 2007-09-06 CA CA2661105A patent/CA2661105C/en active Active
- 2007-09-06 EP EP07826287A patent/EP2069336B1/en active Active
- 2007-09-06 JP JP2009527264A patent/JP5253401B2/ja not_active Expired - Fee Related
- 2007-09-06 SI SI200731169T patent/SI2069336T1/sl unknown
- 2007-09-06 KR KR1020097006862A patent/KR101470659B1/ko not_active Expired - Fee Related
- 2007-09-06 HR HRP20130181TT patent/HRP20130181T1/hr unknown
- 2007-09-06 CL CL200702593A patent/CL2007002593A1/es unknown
- 2007-09-06 ES ES07826287T patent/ES2400533T3/es active Active
- 2007-09-06 CN CN200780033152XA patent/CN101511827B/zh not_active Expired - Fee Related
- 2007-09-06 MX MX2009002233A patent/MX2009002233A/es active IP Right Grant
- 2007-09-06 PL PL07826287T patent/PL2069336T3/pl unknown
- 2007-09-06 DK DK07826287.0T patent/DK2069336T3/da active
- 2007-09-06 AR ARP070103940A patent/AR062683A1/es active IP Right Grant
- 2007-09-06 BR BRPI0716171A patent/BRPI0716171B8/pt not_active IP Right Cessation
- 2007-09-06 MY MYPI20090912A patent/MY149853A/en unknown
- 2007-09-06 WO PCT/IB2007/053594 patent/WO2008029371A1/en not_active Ceased
- 2007-09-06 RU RU2009112538/04A patent/RU2447071C2/ru active
- 2007-09-06 TW TW096133280A patent/TWI392671B/zh not_active IP Right Cessation
2009
- 2009-03-04 IL IL197393A patent/IL197393A/en active IP Right Grant
- 2009-03-18 MA MA31729A patent/MA30718B1/fr unknown
- 2009-04-06 NO NO20091394A patent/NO342156B1/no unknown
2013
- 2013-02-27 CY CY20131100186T patent/CY1113727T1/el unknown

Also Published As

Publication number	Publication date
BRPI0716171A8 (pt)	2017-12-26
CN101511827B (zh)	2012-02-01
MY149853A (en)	2013-10-31
KR101470659B1 (ko)	2014-12-08
BRPI0716171B1 (pt)	2021-05-11
SI2069336T1 (sl)	2013-03-29
RU2009112538A (ru)	2010-10-20
CL2007002593A1 (es)	2008-06-13
EP2069336B1 (en)	2012-12-26
AU2007292993B2 (en)	2013-01-24
HRP20130181T1 (hr)	2013-03-31
CN101511827A (zh)	2009-08-19
EP2069336A1 (en)	2009-06-17
WO2008029371A1 (en)	2008-03-13
PT2069336E (pt)	2013-03-07
KR20090050102A (ko)	2009-05-19
US8580824B2 (en)	2013-11-12
PL2069336T3 (pl)	2013-05-31
NZ576060A (en)	2011-11-25
MA30718B1 (fr)	2009-09-01
CA2661105C (en)	2015-01-06
TW200817357A (en)	2008-04-16
MX2009002233A (es)	2009-03-16
US20100063108A1 (en)	2010-03-11
NO20091394L (no)	2009-04-06
IL197393A0 (en)	2009-12-24
HK1133654A1 (en)	2010-04-01
AR062683A1 (es)	2008-11-26
DK2069336T3 (da)	2013-02-25
IL197393A (en)	2013-09-30
JP5253401B2 (ja)	2013-07-31
NO342156B1 (no)	2018-04-09
AU2007292993A1 (en)	2008-03-13
CA2661105A1 (en)	2008-03-13
CY1113727T1 (el)	2016-06-22
JP2010502695A (ja)	2010-01-28
BRPI0716171B8 (pt)	2021-05-25
RU2447071C2 (ru)	2012-04-10
TWI392671B (zh)	2013-04-11
ES2400533T3 (es)	2013-04-10

Legal Events

Date	Code	Title	Description
2017-12-26	B25A	Requested transfer of rights approved	Owner name: IDORSIA PHARMACEUTICALS LTD (CH)
2018-01-23	B25L	Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled	Owner name: ACTELION PHARMACEUTICALS LTD (CH)
2018-01-30	B25C	Requirement related to requested transfer of rights	Owner name: ACTELION PHARMACEUTICALS LTD (CH)
2018-04-24	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-05-02	B25A	Requested transfer of rights approved	Owner name: IDORSIA PHARMACEUTICALS LTD (CH)
2018-10-23	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-10-01	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2020-11-17	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-12-22	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2021-03-30	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2021-05-11	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/09/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/09/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2024-07-02	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 17A ANUIDADE.
2024-10-15	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2791 DE 02-07-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0716171A2 (pt)	2013-09-17	composto, composiÇço farmacÊutica e uso de um composto.
BRPI0815709A2 (pt)	2017-06-13	composro, composição farmacêutica, e, uso de um composto.
BRPI0810696A2 (pt)	2014-10-21	Composto, composição farmacêutica, e, uso de um composto
BRPI0609802A2 (pt)	2017-05-02	composto, composição farmacêutica e uso de um composto
BRPI0919942A2 (pt)	2014-12-23	Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt)	2017-05-23	composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt)	2015-12-29	composto, composição farmacêutica, e, uso de um composto
BRPI0716698A2 (pt)	2014-02-25	Composto, composição farmacêutica e uso de um composto
BRPI0614205A2 (pt)	2016-11-22	composto, composição farmacêutica, e, uso de composto
BRPI0810161A2 (pt)	2014-12-30	Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
BRPI1007018A2 (pt)	2016-03-29	composto, composição farmacêutica, e , uso de um composto.
BRPI0618904A2 (pt)	2016-09-13	composto, composição farmacêutica, e, uso do composto
BRPI1008906A2 (pt)	2016-03-15	composto, composição farmacêutica, e, uso de um composto.
BRPI0921879A2 (pt)	2018-10-16	composto, composição farmacêutica , e, uso de um composto
BRPI0810019A2 (pt)	2014-10-14	Composto, composição farmacêutica, e, uso de um composto
BRPI0812942A2 (pt)	2014-12-16	Composto, composição farmacêutica e uso de um composto
BRPI0917579A2 (pt)	2016-10-11	composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0814593A2 (pt)	2015-01-20	Composto, composição farmacêutica que o contém e uso do composto.
BRPI0819696A2 (pt)	2015-06-16	Compostos de derivados de 2-fenil-pirimidina, composição farmacêutica e uso de um composto
BRPI0821115A2 (pt)	2015-06-16	Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
CL2007002377A1 (es)	2008-04-04	Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno.
BRPI0906937A2 (pt)	2016-04-19	composto, composição farmacêutica, e, uso de um composto
BRPI0917001A2 (pt)	2016-02-16	composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BRPI1009757A2 (pt)	2016-03-15	composto, composição farmacêutica, e , uso de um composto.
BRPI0915473A2 (pt)	2015-11-10	composto, composição farmacêutica, e, uso de um composto